Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effectiveness of PCV13 in Preventing Vaccine-Type Pneumonia in Children in Suzhou
CTR20180473Phase 4Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of pneumococcal 13-valent conjugate vaccine in Pneumococcal pneumonia (PP), pneumonia, invasive pneumococcal disease (IPD), sponsored by Pfizer. Started Apr 2018; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
Pneumococcal pneumonia (PP)pneumoniainvasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on CTR20180473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180473.